Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)

  Print   

Thursday 23 December, 2021

Tissue Regenix Group

Director/PDMR Shareholding

RNS Number : 5587W
Tissue Regenix Group PLC
23 December 2021
 

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

 

Director/PDMR Shareholding

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that on 22 December 2021, Daniel Lee, Chief Executive Officer, acquired 1,408,450 ordinary shares of 0.1p each in the Group ("Ordinary Shares") at a price of 0.5350 pence per Ordinary Share for a total consideration of £7,535.21.

As a result, Daniel Lee's beneficial interest in the Company is 3,477,200 Ordinary Shares, representing 0.05% of the total issued share capital.

For more information:

 

Tissue Regenix Group plc

David Cocke, Chief Financial Officer

www.tissueregenix.com

Via Walbrook PR

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Alex Price

Tel:  +44(0)20 7710 7600

 

Walbrook PR Ltd

Alice Woodings / Lianne Cawthorne

Tel: +44 (0)20 7933 8780

 [email protected]

 

 

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

 

The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. The notification form is set out below.

 

 

  1

 

Details of the person discharging managerial responsibilities / person closely associated  

a)

 

Name

D R Lee

2

 

Reason for the notification

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a)

 

Name

Tissue Regenix Group plc

b)

 

LEI

 213800PNOD5UHQUFJI36

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

 

Ordinary shares of 0.1p each

 

 

b)

Identification code 

 

GB00B5SGVL29

c)

 

Nature of the transaction 

 

Purchase

d)

 

Price(s) and volume(s)

 

Price

Volume

0.5350p

1,408,450

 

 

 

d)

 

Aggregated information 

- Aggregated volume

- Price

 

 

1,408,450

 

£7,535.21

e)

 

Date of the transaction 

22 December 2021

f)

 

Place of the transaction

London Stock Exchange, AIM Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDDBDDRBDDGBD

a d v e r t i s e m e n t